SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging in community discussions as investors rally behind its organic growth model and active engagement, which is currently focused on regaining its ticker and chart status on major financial platforms. Supporters are framing this as a patient, long-term building project that stands in contrast to the volatility and rug-pull risks often associated with similar meme-themed assets.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently the subject of intense retail and institutional debate, driven by a rare public endorsement from President Trump that triggered a volatile liquidity event amidst broader concerns over AI software valuations. Investors are actively split between those who view the pullback as a buying opportunity based on the company's entrenched government contracts, and skeptics who highlight potential sector-wide rotation out of crowded SaaS and AI-linked positions.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a significant multi-year cloud infrastructure deal with Anthropic to support its Claude models, signaling sustained demand for high-performance AI compute. While the partnership has fueled bullish sentiment around its expanding roster of major AI clients, traders are simultaneously debating the impact of the company's concurrent upsized debt offering and broader market volatility.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the center of intense debate as investors weigh whether the recent sell-off represents a structural reset or a temporary exhaustion event amid fears of AI-driven disruption. While some traders point to deeply oversold technical levels and institutional accumulation as signs of a potential bottom, others argue that valuation compression and the rise of competitive AI models continue to create significant headwinds for traditional SaaS business models.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing aggressive volatility and intense debate, driven by a rapid price surge that has triggered a divide between retail momentum traders and short sellers questioning the company's valuation against its current revenue. The community is actively discussing the stock's parabolic move, the impact of a new capital-raising program, and conflicting perspectives on whether the semiconductor testing equipment maker is an overextended speculative bubble or a long-term play on silicon photonics and AI infrastructure.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened volatility and intense social media discussion as the community reacts to the sentencing of co-founder Do Kwon and persistent rumors regarding exchange delistings and potential token burns. Investors remain deeply divided, with many debating the project's long-term viability under community governance while others leverage the price action to accumulate positions in anticipation of a potential revival.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is facing significant retail skepticism and volatility as investors weigh the company's rebranding to 'HELP' and its transition to a NASDAQ listing against a history of dilution and poor stock performance. The community is actively debating the company's clinical pipelinespecifically Phase 3 MDD and Phase 2 GAD datawhile expressing deep frustration over management's communication, the ticker symbol's irony, and the stock's persistent downward trend.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing a sharp sell-off driven by a UBS downgrade and deepening investor anxiety regarding the potential impact of AI disruption on traditional enterprise software business models. The stock has seen massive volume and heavy put activity as the community debates whether this is a structural repricing of the SaaS sector or a tactical buying opportunity fueled by sentiment exhaustion and extreme oversold conditions.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is capturing investor attention as it re-rates following the termination of its Warner Bros. Discovery merger, with sentiment boosted by positive analyst upgrades and a robust ad-tier growth strategy. Community discussion remains heavily focused on the stock's potential for a breakout as traders position themselves ahead of the upcoming earnings reporting cycle.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing significant investor attention as market participants debate its long-term fundamental value and potential as a core DeFi infrastructure play, fueled by recent governance proposals for token buybacks and strategic roadmap updates. The community remains deeply divided, with many traders highlighting the protocol's institutional utility and undervalued metrics, while others express frustration over price volatility and comparative performance against other DeFi assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 10, 2026 Insiders may stand to receive...

JPMorgan Chase & Co. Sells 181,285 Shares of Apellis Pharmaceuticals, Inc. $APLS

JPMorgan Chase & Co. cut its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 77.2% in the 3rd quarter, according to the company in its most recent disclosure with...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have received an average recommendation of "Hold" from the twenty-three brokerages that are currently covering the firm...

Gilead Expands Oncology Pipeline With $5B Tubulis Deal

Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.

Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lowered its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 61.1% in the fourth quarter, according to the company in its most recent...

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS...

Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 7, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month High - What's Next?

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week High - Here's What Happened...

Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold"

Roth Mkm cut Apellis Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday...

Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00

Mizuho boosted their price objective on shares of Apellis Pharmaceuticals from $20.00 to $41.00 and gave the stock a "neutral" rating in a report on Thursday...

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.34	--	--	N/A
Q4 '25	-$0.38	-$0.47	-24.25%	MISSED
Q3 '25	$1.58	$1.67	5.78%	BEAT
Q2 '25	-$0.48	-$0.33	31.64%	BEAT
Q1 '25	-$0.35	-$0.74	-109.74%	MISSED

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest APLS News

APLSApellis Pharmaceuticals Inc